-
1 Comment
Viva Biotech Holdings is currently in a long term uptrend where the price is trading 20.8% above its 200 day moving average.
From a valuation standpoint, the stock is 79.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 23.5.
Viva Biotech Holdings's total revenue rose by 9.3% to $198M since the same quarter in the previous year.
Its net income has dropped by 341.7% to $-530M since the same quarter in the previous year.
Finally, its free cash flow grew by 126.5% to $10M since the same quarter in the previous year.
Based on the above factors, Viva Biotech Holdings gets an overall score of 4/5.
| Exchange | HK |
|---|---|
| CurrencyCode | HKD |
| Sector | Healthcare |
| ISIN | KYG9390W1015 |
| Industry | Biotechnology |
| Beta | 1.39 |
|---|---|
| PE Ratio | 28.33 |
| Target Price | 3.2501 |
| Market Cap | 4B |
| Dividend Yield | None |
Viva Biotech Holdings, an investment holding company, engages in the provision of structure-based drug discovery services to biotechnology and pharmaceutical customers worldwide. The company provides discovery biology services, including protein expression and purification, structural biology, hit discovery, bioassay, biomolecular interaction, and pharmacology and DMPK; chemistry services, such as medicinal and synthetic chemistry, analytical chemistry, purification preparation, and computer-aided drug design services, as well as offers chemical technology platforms; and antibody/biologics research and development services comprising recombinant protein expression platform, antibody discovery and affinity maturation, assay platform, antibody production and identification platform, and antigen-antibody structural resolution platform solutions. It also offers PROTAC/molecular glue services, including protein preparation and ternary complex structure determination, screening for molecule glues and novel E3 ligase ligands, PROTAC ternary complex kinetics, PROTAC degradation assays and ternary complex assays, PROTAC molecule design and synthesis, ADME & PK/PD studies of PROTAC molecules, and computer aided PROTAC design solutions; and XDC platforms, such as XDC conjugation and quality study, XDC chemistry research and development, and XDC functional studies. In addition, the company offers contract development and manufacturing services comprising integrated services for small molecule active pharmaceutical ingredients, formulation development and production services, and pharmaceutical analysis services, as well as CMC filing, global filing registration support, and other services. Further, it provides research services. The company was incorporated in 2008 and is headquartered in Shanghai, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 1873.HK using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
